Kyverna Therapeutics Business Summary

Kyverna Therapeutics, Inc. (KYTX) is a clinical-stage biopharmaceutical company pioneering the use of chimeric antigen receptor (CAR) T-cell therapies for autoimmune diseases. As of February 2026, the company remains pre-revenue, generating capital primarily through public equity offerings and venture financing to fund its transition toward a commercial-stage entity. Its primary business segments are focused on neuroimmunology and rheumatology, led by its flagship autologous CD19-targeting CAR T-cell candidate, miv-cel (KYV-101). Kyverna is currently advancing toward a Biologics License Application (BLA) submission for Stiff Person Syndrome (SPS) in the first half of 2026 and is conducting a Phase 3 trial for generalized myasthenia gravis. Within the competitive landscape, Kyverna contends with Cabaletta Bio, Quell Therapeutics, and Sangamo Therapeutics; however, it distinguishes itself as a potential first-to-market leader in the autoimmune CAR T space, specifically targeting high-unmet-need orphan indications where it holds a significant clinical head start. The leadership team is anchored by Chief Executive Officer Warner Biddle, who previously served as Senior Vice President of Global Commercial at Gilead’s Kite Pharma, and Chief Technology Officer Mayo Pujols, a veteran of Novartis and Celgene who joined in February 2026 to scale commercial manufacturing. The company was founded by Jeffrey Greve and Dominic Borie, the latter of whom continues to serve as a strategic advisor. Governance is further strengthened by Executive Chairperson Christi Shaw, former CEO of Kite, and a board featuring industry luminaries such as Ian Clark (former CEO of Genentech), Sravan Emany (CFO of Beam Therapeutics), and Andrew Miller (founder of Karuna Therapeutics). Kyverna is backed by a high-pedigree investor base including Bain Capital Life Sciences, Northpond Ventures, and RTW Investments, providing a robust financial runway extending into 2028.